Pulmonary inflammation and glucocorticoid sensitivity for the prediction of bronchopulmonary dysplasia (PRIDICT-BPD): A multicenter study

Pulmonary inflammation and glucocorticoid sensitivity for the prediction of bronchopulmonary dysplasia (PRIDICT-BPD): A multicenter study - Pulmonary Inflammation and Glucocorticoid Sensitivity in Preterm Infants

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50974

Enrollment

375

Registered

2021-03-22

Start date

2022-02-02

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchopulmonary dysplasia chronic lung disease of prematurity

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Newborn infant born

Exclusion criteria

Exclusion criteria: Major congenital anomalies, such as congenital heart and pulmonary defects, and major genetic anomalies. Major surgery in the first 24 hours after birth

Design outcomes

Primary

Measure	Time frame
Primary parameters: 1. Pulmonary inflammation, as assessed from volatile organic compounds (VOCs); 2. Adrenocortical output, as assessed from levels of cortisol, 17-OH progesterone and 11-deoxycortisol; 3. Glucocorticoid tissue-sensitivity, as assessed from single-nucleotide polymorphisms (SNPs) in the glucocorticoid receptor gene and glucocorticoid-responsive genes involved in lung development. Primary outcome: The occurrence and severity of BPD.	—

Measure

Time frame

Primary parameters: 1. Pulmonary inflammation, as assessed from volatile organic compounds (VOCs); 2. Adrenocortical output, as assessed from levels of cortisol, 17-OH progesterone and 11-deoxycortisol; 3. Glucocorticoid tissue-sensitivity, as assessed from single-nucleotide polymorphisms (SNPs) in the glucocorticoid receptor gene and glucocorticoid-responsive genes involved in lung development. Primary outcome: The occurrence and severity of BPD.

—

Secondary

Measure	Time frame
Secondary outcome: Neurocognitive development at 1 and 2 years of corrected age, as assessed from eye tracking at the age (if available in participating center) and the Bayley Scales of Infant Development, respectively.	—

Countries

Netherlands

Contacts

Public ContactM Romijn

Amsterdam UMC

pridict@amsterdamumc.nl0205669111

Outcome results